Literature DB >> 19748095

Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome.

Ulla Vogel1, Stine Segel, Claus Dethlefsen, Anne Tjønneland, Anne Thoustrup Saber, Håkan Wallin, Majken K Jensen, Erik B Schmidt, Paal Skytt Andersen, Kim Overvad.   

Abstract

BACKGROUND: The use of specific COX-2 inhibitors in cancer prevention has been associated with higher risk of acute coronary syndrome (ACS) and myocardial infarction. The aim of this study was to investigate if the polymorphisms COX2 T8473C (rs5275), and COX2 A-1195G (rs689466), which modify the enzyme levels of COX-2, were associated with risk of ACS and if alcohol intake, smoking, and use of NSAID would modify the associations. We also wanted to investigate associations with blood lipid levels.
METHODS: A case-cohort study including 1031 ACS cases and a sub-cohort of 1703 persons was nested within the population-based prospective study Diet, Cancer and Health of 57,053 individuals aged 55-64 at recruitment 1993-1997.
RESULTS: Male variant allele carriers of COX-2 T8473C were at lower risk of ACS (IRR=0.75, CI=0.61-0.93, p=0.008) than homozygous wildtype carriers. There were no statistically significant interactions between genotypes and alcohol intake, smoking and NSAID use in relation to risk of ACS. Among males, there was interaction between COX-2 T8473C and alcohol in relation to total cholesterol, non-HDL cholesterol and LDL levels (p for interaction: 0.003, 0.007 and 0.01, respectively), such that variant allele carriers with low alcohol intake had the lowest lipid levels. No statistically significant associations were observed in females.
CONCLUSION: This study suggests that genetically determined COX-2 levels are associated with risk of ACS and blood lipid levels among males. No consistent associations were found for females.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748095     DOI: 10.1016/j.atherosclerosis.2009.08.036

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene.

Authors:  Patricia McGettigan; Lisa F Lincz; John Attia; Patrick McElduff; Linda Bissett; Roseanne Peel; Barrie Stokes; Stephen Hancock; Kim Henderson; Michael Seldon; David Henry
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

2.  The NFKB1 ATTG ins/del polymorphism and risk of coronary heart disease in three independent populations.

Authors:  Ulla Vogel; Majken K Jensen; Karen Margrete Due; Eric B Rimm; Håkan Wallin; Michael R S Nielsen; Anne-Pernille T Pedersen; Anne Tjønneland; Kim Overvad
Journal:  Atherosclerosis       Date:  2011-06-17       Impact factor: 5.162

3.  Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis.

Authors:  Marina Korotkova; Nina A Daha; Maria Seddighzadeh; Bo Ding; Anca I Catrina; Staffan Lindblad; Tom W J Huizinga; Rene E M Toes; Lars Alfredsson; Lars Klareskog; Per-Johan Jakobsson; Leonid Padyukov
Journal:  Eur J Hum Genet       Date:  2011-03-30       Impact factor: 4.246

4.  Association of cyclooxygenase-2 genetic variant with cardiovascular disease.

Authors:  Stephanie Ross; John Eikelboom; Sonia S Anand; Niclas Eriksson; Hertzel C Gerstein; Shamir Mehta; Stuart J Connolly; Lynda Rose; Paul M Ridker; Lars Wallentin; Daniel I Chasman; Salim Yusuf; Guillaume Paré
Journal:  Eur Heart J       Date:  2014-05-05       Impact factor: 29.983

5.  SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors.

Authors:  Sarah M Rausch; Brian D Gonzalez; Matthew M Clark; Christi Patten; Sara Felten; Heshan Liu; Yafei Li; Jeff Sloan; Ping Yang
Journal:  Lung Cancer       Date:  2012-03-29       Impact factor: 5.705

6.  PharmGKB summary: very important pharmacogene information for PTGS2.

Authors:  Caroline F Thorn; Tilo Grosser; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

7.  Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes.

Authors:  Vibeke Andersen; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

8.  No association of nineteen COX-2 gene variants to preclinical markers of atherosclerosis The Cardiovascular Risk in Young Finns Study.

Authors:  Kati Lähteelä; Tarja Kunnas; Leo-Pekka Lyytikäinen; Nina Mononen; Leena Taittonen; Tomi Laitinen; Johannes Kettunen; Markus Juonala; Nina Hutri-Kähönen; Mika Kähönen; Jorma S Viikari; Olli T Raitakari; Terho Lehtimäki; Seppo T Nikkari
Journal:  BMC Med Genet       Date:  2012-07-02       Impact factor: 2.103

9.  Interaction between obesity and the NFKB1 - 94ins/delATTG promoter polymorphism in relation to incident acute coronary syndrome: a follow up study in three independent cohorts.

Authors:  Jakob Gerhard Stegger; Erik Berg Schmidt; Tina Landsvig Berentzen; Anne Tjønneland; Ulla Vogel; Eric Rimm; Thorkild I A Sørensen; Kim Overvad; Majken K Jensen
Journal:  PLoS One       Date:  2013-05-09       Impact factor: 3.240

10.  Cyclooxygenase and prostaglandin in cancer.

Authors:  Jong-Woo Kim
Journal:  J Korean Soc Coloproctol       Date:  2012-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.